Efficacy of sacituzumab govitecan versus treatment of physician's choice in previously treated HR+ and HER2- mBC: a meta-analysis of TROPiCS-02 and EVER-132-002 trials.

ABSTRACT:

Background and objective

TROPiCS-02 and EVER-132-002 are phase III randomized controlled trials (RCTs) comparing sacituzumab govitecan (SG) to treatment of physician's choice (TPC) in patients with hormone receptor-positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) locally recurrent inoperable or metastatic breast cancer (mBC) who have progressed after two to four prior chemotherapy regimens. TROPiCS-02 enrolled mainly non-Asian patients, whereas EVER-132-002 consisted of only Asian participants. In this study, we compared the efficacy outcomes for SG to TPC via a meta-analysis of the two trials.

Methods

Preferred Reporting Items for Systematic Reviews and Meta-Analyses of Individual Participant Data (PRISMA-IPD) guidelines were followed. IPD from the

SUBMITTER: Gluz O 

PROVIDER: S-EPMC11907608 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature